DNA-encoded compound libraries and methods for screening compounds

By incorporating covalent cross-linking in DNA-encoded compounds, the screening efficiency and discrimination of low-affinity compounds are enhanced, addressing the limitations of traditional affinity-based DNA-encoded libraries.

JP7592164B2Active Publication Date: 2024-11-29HITGEN INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023532256
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-11-27
Filing Date
2021-11-24
Publication Date
2024-11-29
Estimated Expiration
2041-11-24

AI Technical Summary

Technical Problem

Traditional DNA-encoded compound libraries face limitations in screening efficiency, particularly for low-affinity compounds, as they rely on affinity screening which can lead to separation of weakly bound molecules during elution, reducing signal enrichment and detection.

Method used

Enhance the binding of compounds to targets through covalent cross-linking using DNA-encoded compounds with specific structural modifications, allowing for improved discrimination and signal detection of low-affinity compounds.

Benefits of technology

The covalent cross-linking approach significantly improves the discrimination and recovery of low-affinity compounds, enhancing the screening efficiency and signal detection in DNA-encoded compound libraries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592164000035
    Figure 0007592164000035
  • Figure 0007592164000036
    Figure 0007592164000036
  • Figure 0007592164000037
    Figure 0007592164000037
Patent Text Reader

Abstract

A method for synthesizing and screening a DNA-encoded compound library is provided. The DNA-encoded compound library can enhance the binding between compounds and targets through covalent cross-linking, thereby improving the discrimination of screening signals for compounds, particularly low-affinity compounds (including fragment compounds), compared to conventional DNA-encoded compound library affinity screening.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to DNA-encoded compounds and methods for synthesizing and screening libraries of such compounds. [Background technology]

[0002] In drug development, especially in new drug development, high-throughput screening for biological targets is one of the main means to rapidly obtain lead compounds. However, traditional high-throughput screening based on single molecules requires long turnaround times, huge equipment investment, limited number of library compounds (millions), and decades of construction of compound libraries, limiting the efficiency and potential of lead compound discovery. The recently emerged DNA-encoded compound library technology (WO2005058479, WO2018166532, CN103882532) incorporates combinatorial chemistry and molecular biology techniques, attaches a single DNA tag to each compound at the molecular level, and can synthesize billions of compound libraries in an extremely short time, becoming the trend of next-generation compound library screening technology, which has begun to be widely applied in the pharmaceutical industry and has produced many positive effects (Accounts of Chemical Research, 2014, 47, 1247-1255).

[0003] When screening drugs using a conventional DNA-encoded chemical library, the chemical library is first incubated with the target, and then the compounds bound to the target are separated from other compounds by elution. The compounds bound to the target are then released under protein denaturing conditions, and QPCR amplification, DNA sequencing, and data analysis are performed to obtain the chemical structures of the compounds bound to the target protein (Figure 1). However, although DNA-encoded chemical screening is an affinity screening, which depends on the magnitude of the interaction force between the drug molecule and the target, and can find molecules with affinity for the target, there are limitations to its application. Mainly, it needs to be eluted during the screening process, and molecules with low affinity (μmol-mmol) are easily separated from the target during the elution process, so the signal cannot be enriched and may be ignored. As a result, the screening effect of DNA-encoded chemical libraries is limited, especially the screening results in the mixed screening process of small molecule fragments.

[0004] In order to solve the above technical problems, the present invention provides a DNA-encoded compound, a compound library and a screening method. The DNA-encoded compound library of the present invention can be used to incubate with a target, and further enhance the binding between the compound and the target through covalent cross-linking, which can improve the discrimination of the screening signal of compounds, especially low affinity compounds, compared with the conventional DNA-encoded compound library affinity screening. Summary of the Invention

[0005] In accordance with the present invention, there is provided a DNA-encoded compound having the general formula represented by Formula I: JPEG0007592164000001.jpg3484 where X is an atom or a molecular skeleton; A1 is a moiety comprising a linker and an oligonucleotide, A2 is a moiety containing a linker and an oligonucleotide, and the oligonucleotide moieties in A1 and A2 are complementary or partially complementary to form a double strand; L is a linking moiety that contains one or more engineered covalently crosslinkable groups; M is a functional moiety that comprises one or more structural units. Furthermore, X is a carbon atom, a nitrogen atom, or a cyclic or acyclic skeletal structure.

[0006] Furthermore, the general formula I has a structure represented by formula II. JPEG0007592164000002.jpg2380, wherein Z1 is an oligonucleotide bound at its 3' end to L1 and Z2 is an oligonucleotide bound at its 5' end to L2, or Z1 is an oligonucleotide bound at its 5' end to L1 and Z2 is an oligonucleotide bound at its 3' end to L2; L1 is a linker containing a functional group capable of forming a bond with the 3' end or 5' end of Z1, L2 is a linker containing a functional group capable of forming a bond with the 5'-end or 3'-end of Z2. More specifically, Z1 and Z2 are complementary or partially complementary to form a double strand, and Z1 and Z2 each have a length of 10 or more bases and a complementary region of 10 or more base pairs. More specifically, Z1 and Z2 each contain a PCR primer sequence. More specifically, L1 and L2 are each independently selected from a difunctional alkylene chain or a difunctional oligomeric glycol chain, and the functional groups are selected from a phosphate group, an amino group, a hydroxyl group, and a carboxyl group.

[0007] More specifically, L1 and L2 are each independently JPEG0007592164000003.jpg1871, where n is an integer from 1 to 10. Preferably, n is an integer from 2 to 6. More preferably, n is 3.

[0008] More specifically, L comprises a photolabile group, an electrolabile group or other group capable of covalently cross-linking with a protein.

[0009] More specifically, L includes an acridinyl group, an aryl azide group, a benzophenone group, a sulfonyl fluoride group, an α,β-unsaturated acid group, an α,β-unsaturated ketone group, an α,β-unsaturated ester group, an α,β-unsaturated sulfonyl group, an α-acyl halide group, an epoxy group, an aldehyde group, a cyano group, or a boronic acid group.

[0010] More specifically, L has the structure -S1-S2-S3-. wherein S1 and S3 are cyclic or acyclic carbon or heteroatom linkers carrying one or more functional groups selected from phosphate, amino, hydroxyl, carboxyl, aldehyde, azide, alkynyl, and halide. S2 is a linker that contains one or more engineered covalently crosslinkable groups.

[0011] In some embodiments of the invention, S1 is bound to X and S3 is bound to M. In other embodiments of the invention, S3 is bound to X and S1 is bound to M.

[0012] More specifically, S1 and S3 are each independently JPEG0007592164000004.jpg30131, or a combination of multiple types selected from these. Here, m is an integer of 1 to 20. The absence of S1 or S3 means that the two moieties bound thereto are directly bound by a covalent bond. Preferably, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0013] More specifically, the engineered covalently crosslinkable group in S2 is directly attached to the linker, JPEG0007592164000005.jpg33131, where R1 is a carbon atom or a nitrogen atom, and R2 is hydrogen, an alkane or aromatic hydrocarbon containing carbon or heteroatoms.

[0014] In some specific embodiments of the invention, S2 is JPEG0007592164000006.jpg55131, where R1 is a carbon atom or a nitrogen atom, and R2 is an alkane or aromatic hydrocarbon containing hydrogen, carbon or heteroatoms.

[0015] In a preferred embodiment of the invention, S2 is Selected from JPEG0007592164000007.jpg1731.

[0016] More specifically, the distance between the engineered covalently crosslinkable group and the functional moiety M is 30 atoms or less. Preferably, the distance between the engineered covalently crosslinkable group and the functional moiety M is 20 atoms or less. More preferably, the distance between the engineered covalently crosslinkable group and the functional moiety M is 15 atoms or less.

[0017] More specifically, the distance between the engineered covalently crosslinkable group and the functional moiety M is greater than 3 atoms. Preferably, the distance between the engineered covalently crosslinkable group and the functional moiety M is greater than 4 atoms. More preferably, the distance between the engineered covalently crosslinkable group and the functional moiety M is greater than 5 atoms.

[0018] More specifically, X is JPEG0007592164000008.jpg28133, where q is an integer of 1 to 10. The oxygen atom in the structural formula is bonded to L1 or L2, respectively.

[0019] In some specific embodiments of the invention, the DNA encoded compound of formula I is JPEG0007592164000009.jpg116133, or a combination of multiple types selected from these. Here, m is an integer of 1 to 20. The absence of S1 or S3 means that the two moieties bound thereto are directly bound by a covalent bond. Preferably, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. M is a functional moiety that comprises one or more structural units.

[0020] The present invention further provides a DNA-encoded compound library comprising the above DNA-encoded compounds.

[0021] Further, the DNA-encoded chemical library comprises at least 10 different DNA-encoded chemical compounds. 2 In some embodiments of the present invention, the term "different DNA encoded compounds" refers to DNA encoded compounds that differ only in their oligonucleotide and functional portions.

[0022] The present invention further provides a starting fragment compound for synthesizing a DNA-encoded chemical library having the structure represented by Formula III. JPEG0007592164000010.jpg2380 where X is an atom or a molecular skeleton; Z1 is an oligonucleotide bound at its 3' end to L1 and Z2 is an oligonucleotide bound at its 5' end to L2, or Z1 is an oligonucleotide bound at its 5' end to L1 and Z2 is an oligonucleotide bound at its 3' end to L2. L1 is a linker containing a functional group capable of forming a bond with the 3' end or 5' end of Z1, L2 is a linker containing a functional group capable of forming a bond with the 5' end or 3' end of Z2, L is a linking moiety that contains one or more engineered covalently crosslinkable groups; R is a reactive group attached to the functional moiety.

[0023] Furthermore, X is a carbon atom, a nitrogen atom, or a cyclic or acyclic skeletal structure.

[0024] Furthermore, Z1 and Z2 are complementary or partially complementary to form a double strand, and the length of Z1 and Z2 is 5 to 15 bases each.

[0025] Further, L1 and L2 are each independently selected from a difunctional alkylene chain or a difunctional oligomeric glycol chain, and the functional group is selected from a phosphate group, an amino group, a hydroxyl group, and a carboxyl group. Additionally, L comprises a photolabile group, an electrolabile group, or other group capable of covalently cross-linking with a protein, and R is selected from a phosphate group, an amino group, a hydroxyl group, a carboxyl group, and an aldehyde group. Furthermore, X is JPEG0007592164000011.jpg28133, where q is an integer of 1 to 10, and the oxygen atom in the structural formula is bonded to L1 or L2, respectively.

[0026] Furthermore, L1 and L2 are each independently JPEG0007592164000012.jpg1871, where n is an integer of 1 to 10, preferably 2 to 6. More preferably, n is 3.

[0027] Furthermore, L has the structure -S1-S2-S3-, where S1 and S3 are linkers consisting of cyclic or acyclic carbon or heteroatoms carrying one or more functional groups selected from phosphate, amino, hydroxyl, carboxyl, aldehyde, azide, alkynyl, and halides, and S2 is a linker containing one or more groups that can be engineered to be covalently crosslinked.

[0028] More specifically, S1 and S3 are each independently JPEG0007592164000013.jpg30131, or a combination of multiple types selected from these. Here, m is an integer of 1 to 20. The absence of S1 or S3 means that the two moieties bound thereto are directly bound by a covalent bond. Preferably, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0029] More specifically, the engineered covalently crosslinkable group in S2 is directly attached to the linker, JPEG0007592164000014.jpg33131, where R1 is a carbon atom or a nitrogen atom, and R2 is hydrogen, an alkane or aromatic hydrocarbon containing carbon or heteroatoms.

[0030] In some specific embodiments of the invention, S2 is JPEG0007592164000015.jpg51131, where R1 is a carbon atom or a nitrogen atom, and R2 is hydrogen, an alkane or an aromatic hydrocarbon containing carbon atoms or heteroatoms.

[0031] In a preferred embodiment of the invention, S2 is JPEG0007592164000016.jpg2031

[0032] More specifically, the distance between the engineered covalently crosslinkable group and R is 30 atoms or less. Preferably, the distance between the engineered covalently crosslinkable group and R is 20 atoms or less. More preferably, the distance between the engineered covalently crosslinkable group and R is 15 atoms or less.

[0033] More specifically, the distance between the engineered covalently crosslinkable group and R is greater than 3 atoms. Preferably, the distance between the engineered covalently crosslinkable group and R is greater than 4 atoms. More preferably, the distance between the engineered covalently crosslinkable group and R is greater than 5 atoms.

[0034] In some specific embodiments of the present invention, the starting fragment compound of a DNA-encoded chemical library represented by formula III is JPEG0007592164000017.jpg115133, or a combination of multiple types selected from these. Here, m is an integer of 1 to 20. The absence of S1 or S3 means that the two moieties bound thereto are directly bound by a covalent bond. Preferably, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. R is a reactive group attached to the functional moiety. Preferably, R is selected from a phosphate group, an amino group, a hydroxyl group, a carboxyl group, and an aldehyde group.

[0035] More specifically, the starting fragment compound has the following structure: JPEG0007592164000018.jpg147134, where R1 is a carbon atom or a nitrogen atom, and R2 is hydrogen, an alkane or an aromatic hydrocarbon containing carbon atoms or heteroatoms.

[0036] According to the present invention, a step a of incubating the compound library with a protein target and then manipulating it to effect covalent cross-linking; a step b of separating the protein-DNA encoded compound covalently cross-linked complex from uncross-linked DNA encoded compound; Step c: subjecting the recovered protein-DNA-encoded compound covalently cross-linked complex to PCR amplification and DNA sequencing to read DNA sequence information and obtain compound structure information; Further provided is a method for screening said DNA-encoded chemical library comprising:

[0037] Furthermore, in the step a, the covalent crosslinking is carried out by light irradiation, heating, electric current or direct incubation.

[0038] Furthermore, the separation method in step b involves immobilizing the protein and washing with an eluent to remove unimmobilized substances.

[0039] Additionally, proteins are immobilized using magnetic beads.

[0040] By screening using the DNA-encoded compound library of the present invention, the binding between the compound and the target can be enhanced by covalent cross-linking, thereby improving the discrimination of screening signals of compounds (especially low affinity compounds and fragment compounds).

[0041] The term "functional moiety" in the present invention refers to a small molecule moiety in a DNA-encoded chemical library, which is used to construct various molecular structures by combinatorial or non-combinatorial chemistry means and screen them with biological targets. The carbon atom described in the present invention can be freely selected according to the understanding of those skilled in the art, for example, "CH2" in the case of divalent substitution and "CH" in the case of trivalent substitution.

[0042] The "molecular skeleton" and "skeleton structure" described in the present invention can freely select the corresponding number of substitutions according to the understanding of a person skilled in the art. For example, in the case of a divalent substitution, there are two substitution sites, and in the case of a trivalent substitution, there are three substitution sites.

[0043] The "oligonucleotide" according to the present invention includes, but is not limited to, DNA, RNA, PNA, etc., and combinations thereof, and a person skilled in the art may determine the sequence information based on the common technical knowledge and conventional methods in the relevant technical field.

[0044] The DNA-encoded chemical library of the present invention is applicable to screening of various biological targets. Those skilled in the art can select different DNA-encoded chemical libraries of the present invention according to their needs.

[0045] The engineered covalently crosslinkable groups in the DNA-encoded compounds / libraries of the present invention are directly attached to a linker, thereby greatly reducing non-specific covalent binding of the covalent crosslinking groups.

[0046] Based on the contents of the present invention, a person skilled in the art can select functional groups suitable for pairing and binding in the starting fragment compounds of the DNA-encoded compounds and the encoded compound library using common technical knowledge and conventional techniques in the art.

[0047] Based on the above content of the present invention, various modifications, substitutions, or changes can be made according to common technical knowledge and conventional means in the relevant technical field without departing from the technical spirit of the present invention.

[0048] The present invention will be described in more detail below with reference to examples and specific embodiments. However, the scope of the present invention is not limited to the following examples. Any technology realized based on the above content of the present invention is included in the scope of the present invention. [Brief description of the drawings]

[0049] [Figure 1] A conventional DNA-encoded chemical library screening process. [Diagram 2] 1 shows examples of four types of DNA-encoded compounds synthesized in Example 1. [Diagram 3] Examples of four compounds whose Kd values ​​were measured in Example 1, with Kd values ​​increasing sequentially for the CAIX target, i.e., decreasing affinity, where the R1 moiety is a fluorescent group and is used to measure the Kd values. [Figure 4] A screening process for DNA-encoded compounds. [Diagram 5]1 shows the results of screening recovery rates of DNA-encoded compounds in Example 1. [Figure 6] 1 shows the results of screening signals from the DNA-encoded chemical library in Example 2. [Figure 7] FIG. 2 is a schematic diagram of the structure of the DNA-encoded compound library constructed in Example 3. [Figure 8] 1 shows the results of screening signals from the DNA-encoded chemical library in Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] The technical means of the present invention will be described more completely and clearly through the following specific examples. The following examples are only some of the examples of the present invention, but not all of them. The raw materials and equipment used in the present invention are all known products and can be obtained by commercial purchase.

[0051] DNA-NH2 or JPEG0007592164000019.jpg47133In the formula, A is adenine, T is thymine, C is cytosine, and G is guanine. Fmoc: fluorenylmethoxycarbonyl; DMT-MM: 2-chloro-4,6-dimethoxy-1,3,5-triazine; DIPEA: N,N-diisopropylethylamine; DMA: N,N-dimethylacetamide; HATU: 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate.

[0052] Example 1: Synthesis and screening of DNA-encoded compounds Step 1: Synthesis of DNA-encoded compounds JPEG0007592164000020.jpg77127

[0053] (1) DNA-NH2 was dissolved in 250 mM pH=9.4 borate buffer to prepare a 1 mM solution, and then mixed with compound 1 (50 equivalents, 200 mM DMA solution), HATU (50 equivalents, 400 mM DMA solution), and DIPEA (100 equivalents, 400 mM DMA solution), each of which had been cooled in a -20°C refrigerator for 5 minutes, and then stored in a 4°C refrigerator for 5 minutes. The prepared DNA-NH2 solution was added to the mixture, and the reaction solution was thoroughly and uniformly mixed by vortex shaking, and the reaction solution was allowed to stand at room temperature for 12 hours. After the reaction was completed, ethanol precipitation was performed. 10% of the total volume of 5M sodium chloride solution was added to the solution, followed by adding 3 times the total volume of anhydrous ethanol. After shaking evenly, the reaction solution was frozen in dry ice for 2 hours, and then centrifuged at a rotation speed of 12,000 rpm for 0.5 hours. The supernatant was discarded, and the remaining precipitate was dissolved in deionized water to obtain the crude product of compound 2. The crude product was used directly in the next reaction without purification.

[0054] (2) The crude product of compound 2 obtained above was dissolved in pure water to prepare a 1 mM solution, and piperidine was added to this solution in an amount of 10% of the total volume. After mixing thoroughly and uniformly by vortex shaking, the reaction solution was reacted at room temperature for 1-3 hours. After the reaction was completed, ethanol precipitation was performed, and 5M sodium chloride solution was added to the solution in an amount of 10% of the total volume, followed by anhydrous ethanol in an amount three times the total volume. After shaking uniformly, the reaction solution was frozen in dry ice for 2 hours, and then centrifuged at a rotation speed of 12,000 rpm for 0.5 hours. The supernatant was discarded, and the remaining precipitate was dissolved in deionized water to obtain the crude product of compound 3. The crude product was used in the next reaction without purification.

[0055] (3) The above obtained compound 3 was dissolved in 250 mM pH=9.4 borate buffer to prepare a 1 mM solution, to which carboxylic acid compound 4 (100 equivalents, 100 mM DMA solution) and DMT-MM solution (100 equivalents, 100 mM deionized water solution) were added in that order, and the mixture was thoroughly and uniformly mixed by vortex shaking. The reaction solution was then allowed to stand at room temperature for 12-16 hours. After the reaction was completed, ethanol precipitation was performed. 10% of the total volume of 5M sodium chloride solution was added to the solution, followed by adding 3 times the total volume of anhydrous ethanol. After shaking evenly, the reaction solution was frozen in dry ice for 2 hours, and then centrifuged at a rotation speed of 12,000 rpm for 0.5 hours. The supernatant was discarded, and the remaining precipitate was dissolved in deionized water to obtain a crude product of compound 5. The crude product was purified by preparative chromatography to obtain pure compound 5.

[0056] (4) 100 nmol of compound 5 obtained above was dissolved in pure water to prepare a 1 mM solution (100 uL), and primer 1 (166.6 nmol, 1.67 equivalents, 2 mM aqueous solution, 83.3 uL), 10x ligation buffer (66.6 uL), T4 DNA ligase (9.6 uL, 13.97 ug / uL) and deionized water (407 uL) were added, vortexed and then reacted at 20°C for 16 hours.

[0057] After the reaction was completed, ethanol precipitation was performed. 10% of the total volume of 5M sodium chloride solution was added to the solution, followed by adding 3 times the total volume of absolute ethanol. After shaking uniformly, the reaction solution was frozen in dry ice for 2 hours, and then centrifuged at a rotation speed of 12,000 rpm for 0.5 hours. The supernatant was discarded, and the remaining precipitate was dissolved in deionized water to obtain a crude product.

[0058] The above crude product was dissolved in pure water to prepare a 1 mM solution (100 uL), and the combined DNA fragment 1-DNA fragment 2-DNA fragment 3-primer 2-primer ID (100 nmol, 1 equivalent, 2 mM aqueous solution, 50 uL), 10x ligation buffer (80 uL), T4 DNA ligase (4.31 uL, 13.97 ug / uL) and deionized water (165 uL) were added. The reaction mixture was vortexed and then reacted at 20°C for 16 hours.

[0059] After the reaction was completed, ethanol precipitation was performed. 5M sodium chloride solution was added to the solution at a volume of 10% of the total volume, followed by the addition of anhydrous ethanol at a volume three times the total volume. After shaking uniformly, the reaction solution was frozen in dry ice for 2 hours, and then centrifuged at a rotation speed of 12,000 rpm for 0.5 hours. The supernatant was discarded, and the remaining precipitate was dissolved in deionized water to obtain compound 6.

[0060] Four types of compound 6 (compound 6-1, compound 6-2, compound 6-3, and compound 6-4) were synthesized by the above synthesis method. The specific structures are shown in Figure 2.

[0061] Step 2: DNA-encoded compound screening A final concentration of 0.2 nM DNA-encoded compound and 100 pmol target protein were added to a total volume of 100 μL screening buffer (screening buffer components: 12.5 mM Tris, 150 mM NaCl, 0.3 mg / mL ssDNA, 0.05% Tween 20, pH 7.5) in a 1.5 mL centrifuge tube. A blank control group (no target protein added) was also prepared. There were two target protein groups and two blank control groups. The centrifuge tubes containing the reactants were placed on a rotating mixer and incubated at 20 rpm and 25°C for 60 min. The incubated samples (one group each of the target group and blank control group) were irradiated under UV conditions at 365 nm for 10 min on ice to perform the photocrosslinking reaction. The other group of samples (one group each of the target group and blank control group) was left on ice for 10 min without UV irradiation at 365 nm.

[0062] 25 μL of Ni-charged magnetic beads, after equilibration with 250 μL screening buffer three times, were added to the samples irradiated with or without UV light, the centrifuge tubes were placed on a rotating mixer and incubated at 20 rpm and 25°C for 30 min, and the target protein and the complex of the DNA-encoded compound bound to the target protein were separated from the solution by a magnetic stand due to the affinity between the target protein tag and the specific magnetic beads, and the supernatant was collected and stored.

[0063] The separated magnetic beads were resuspended in 500 μL screening buffer and washed for 1 min at 20 rpm and 25°C using a rotary mixer to remove non-specifically bound DNA-encoded compounds, and the magnetic beads and supernatant were separated using a magnetic stand. This was repeated five times. The washed magnetic beads were resuspended in 100 μL elution buffer (12.5 mM Tris, 150 mM NaCl, pH 7.5) and eluted for 10 min by heating to 95°C in a metal bath. The magnetic beads and the eluted DNA-encoded compounds were separated using a magnetic stand. The bound DNA-encoded compound sample was obtained by photocrosslinking. The eluted supernatant was the DNA-encoded compound sample obtained by affinity interaction.

[0064] The eluted supernatant and beads were diluted 20-fold using dilution buffer (10 mM Tris, pH 8.0, 0.05% Tween 20), and the DNA-encoded compound was diluted 100-fold. The above samples, primers, deionized water, and qPCR mix (ABI, A25778) were prepared into 20 uL of reaction solution, and qPCR detection was performed under the conditions of 95 ° C, 10 min pre-denaturation, 35 cycles (95 ° C, 10 s denaturation; 55 ° C, 10 s annealing; 72 ° C, 10 s extension). Signal collection was set up at the extension step. After the qPCR reaction was completed, the sample molecular copy number was calculated using the Avogadro constant, and the difference in molecular copy number between samples was analyzed.

[0065] The above screening test results are shown in Figure 5. As can be seen from the test results, under conventional DNA-encoded compound library screening conditions (non-illumination conditions), the DNA recovery ratio ranges from 0.51 to 1.67, and the screening signals have no obvious discrimination. In the DNA-encoded compounds and screening methods of the present invention, the DNA recovery ratio ranges from 2.27 to 151.92, and the discrimination of the screening signals is significantly improved, and the recovery ratio is positively correlated with the activity of the compounds (Figure 3).

[0066] Example 2: Synthesis of a DNA-encoded chemical library and screening with a phosphatase target

[0067] Using the starting DNA (compound 3) produced in Example 1 as a raw material, a DNA-encoded compound library containing 962 compounds and having the following structure was constructed by the DNA-encoded compound library construction method described in WO2005058479. JPEG0007592164000021.jpg28131The above compound library was screened in steps.

[0068] (1) In a 1.5 mL centrifuge tube, a DNA-encoded chemical library with a final concentration of 5.65 nM and 250 pmol of target protein were added to a total volume of 100 μL of screening buffer (screening buffer components: 50 mM HEPES, 150 mM NaCl, 0.01% Tween-20, 0.3 mg / mL ssDNA, 10 mM imidazole, pH 7.4), and a blank control group (no target protein added) was also prepared. Two target protein groups and two blank control groups were prepared. The centrifuge tubes containing the reactants were placed on a rotating mixer and incubated at 20 rpm and 25°C for 60 min. After incubation, the samples (one group each of the target group and blank control group) were irradiated with 365 nm UV light on ice for 10 min to perform photocrosslinking reaction. The other group of samples (one group each of the target group and blank control group) was not irradiated with 365 nm UV light and was left on ice for 10 min.

[0069] (2) 20 μL of Ni-charged magnetic beads, after equilibration with 200 μL screening buffer three times, were added to the samples irradiated with or without UV light, the centrifuge tubes were placed on a rotating mixer and incubated at 20 rpm and 25°C for 30 min. Due to the affinity between the target protein tag and the specific magnetic beads, the target protein and the complex of the DNA-encoded compound bound to the target protein were separated from the solution by a magnetic stand, and the supernatant was collected and stored.

[0070] (3) The separated magnetic beads were resuspended in 500 μL of screening buffer, washed for 1 min at 20 rpm and 25°C using a rotary mixer to remove non-specifically bound DNA-encoded compounds, and the magnetic beads and supernatant were separated using a magnetic stand. This was repeated five times.

[0071] (4) The washed magnetic beads were resuspended in 55 μL elution buffer (50 mM HEPES, 300 mM NaCl, pH 7.4) and eluted for 10 min by heating to 95°C in a metal bath. The magnetic beads and the eluted DNA-encoded compounds were separated using a magnetic stand. The bound DNA-encoded compound sample was obtained by photocrosslinking. The eluted supernatant was the DNA-encoded compound sample obtained by affinity interaction.

[0072] (5) The eluted supernatant and beads were diluted 20 times using dilution buffer (10 mM Tris, pH 8.0, 0.05% Tween 20), and the DNA-encoded compound was diluted 100 times. The above samples, primers, deionized water and qPCR mix (ABI, A25778) were prepared into 20 uL of reaction solution, and qPCR detection was performed under the conditions of 95 ° C, 10 min pre-denaturation, 35 cycles (95 ° C, 10 s denaturation; 55 ° C, 10 s annealing; 72 ° C, 10 s extension). Signal collection was set up at the extension step. After the qPCR reaction was completed, the sample molecular copy number was calculated using the Avogadro constant, and the difference in molecular copy number between samples was analyzed.

[0073] The test results obtained by the above compound library and screening method are shown in Figure 6. In Figure 6, the ordinate S3 / S4 elution is the result of the conventional DNA-encoded compound library screening signal, and the value of the ordinate is the DNA recovery ratio. As can be seen from the results, the DNA recovery ratio of all compounds is 0-2, and there is no obvious signal differentiation. In Figure 6, the abscissa S1 / S3 beads is the result of the DNA-encoded compound library screening signal of the present invention, and the value of the ordinate is the DNA recovery ratio. As can be seen from the results, the DNA recovery ratio of the compounds is 0-60, and there is obvious signal differentiation.

[0074] Example 3: Synthesis of DNA-encoded chemical libraries and screening for kinase targets According to the method for constructing a DNA-encoded chemical library described in Example 1 and WO2005058479, a DNA-encoded chemical library was constructed containing 7417 compounds as shown in Figure 7, where L is a linker of different lengths. According to the screening method of Example 2, the above compound library was used to screen the kinase target PAK4. Each group of screening is shown in Table 1. In Table 1, "+" means that there is a corresponding condition, and "-" means that there is no corresponding condition.

[0075] Table 1: Screening group status JPEG0007592164000022.jpg33137

[0076] The results of the screening signal are shown in FIG. 8. In FIG. 8, the horizontal ordinate indicates the screening signal enrichment status (molecule enrichment status) of different screening groups, and the numerical value indicates the enrichment degree. FIG. 1 to FIG. 4 show that the compound library and screening method of the present invention can obtain a better signal enrichment status. FIG. 1 also shows that the molecules are not enriched to materials other than proteins (e.g., magnetic beads, etc.). FIG. 2 shows that the enrichment degree of the molecules is much higher in the covalent crosslinking by light irradiation than the enrichment degree under non-light irradiation conditions. FIG. 3 shows that the signal intensity of the molecules is reduced by the competing molecules, indicating that they act on the correct target pocket. FIG. 4 shows that the molecules do not cause severe non-specific binding.

[0077] As can be seen from the test results, the DNA-encoded compound / library and screening method of the present invention can enhance the binding between the compound and the target, improve the discrimination in the screening signals of compounds, especially low affinity compounds, and have a positive effect.

[0078] As described above, the present invention provides a method for synthesizing and screening DNA-encoded compounds and compound libraries. The DNA-encoded compound library of the present invention is incubated with a target, and the binding between the compound and the target can be enhanced by covalent cross-linking, which can improve the discrimination of screening signals of compounds, especially low affinity compounds, compared with conventional DNA-encoded compound library affinity screening.

Claims

1. A DNA-encoded compound having the structure represented by Formula II: 【Chemistry 1】 Formula II (In the formula, Z 1 has L at its 3' end 1 Z is an oligonucleotide linked to 2 has a 5′ end L 2 or an oligonucleotide linked to Z 1 has a 5′ end L 1 Z is an oligonucleotide linked to 2 has L at its 3' end 2 is an oligonucleotide linked to L 1 and L 2 are each independently 【Chemistry 2】 where n is an integer from 1 to 10; X is a nitrogen atom, 【Chemistry 3】 where q is an integer from 1 to 10; L is -S 1 -S 2 -S 3 - has the structure S 1 and S 3 are each independently 【Chemistry 4】 or absent, where m is an integer from 1 to 20; S 2 teeth, 【Chemistry 5】 The structure is M is a small molecule moiety in a DNA-encoded chemical library that is used to screen with a biological target.

2. Z 1 and Z 2 is complementary or partially complementary to form a double strand, and Z 1 and Z 2 2. The DNA-encoded compound of claim 1, wherein each of said sequences is 10 or more bases in length and has 10 or more base pair complementary regions.

3. Z 1 and Z 2 The DNA-encoded compound of claim 2 , wherein each of said sequences comprises a PCR primer sequence.

4. A DNA-encoded compound library, comprising the DNA-encoded compound according to any one of claims 1 to 3.

5. The DNA-encoded compound library comprises at least 10 2 5. The DNA-encoded chemical library of claim 4, comprising different species of DNA-encoded chemical compounds.

6. A starting fragment compound for synthesizing a DNA-encoded chemical library, characterized in that it has the structure represented by Formula III below: 【Chemistry 6】 Formula III (In the formula, Z 1 has L at its 3' end 1 Z is an oligonucleotide linked to 2 has a 5′ end L 2 or an oligonucleotide linked to Z 1 has a 5′ end L 1 Z is an oligonucleotide linked to 2 has L at its 3' end 2 is an oligonucleotide linked to L 1 and L 2 are each independently 【Chemistry 7】 where n is an integer from 1 to 10; X is a nitrogen atom, 【Chemistry 8】 where q is an integer from 1 to 10; L is -S 1 -S 2 -S 3 - has the structure S 1 and S 3 are each independently 【Chemistry 9】 or absent, where m is an integer from 1 to 20; S 2 teeth, 【Chemistry 10】 The structure is R is selected from a phosphate group, an amino group, a hydroxyl group, a carboxyl group, and an aldehyde group.

7. Z 1 and Z 2 is complementary or partially complementary to form a double strand, and Z 1 and Z 2 The starting fragment compound according to claim 6, characterized in that each of the lengths of said fragments is 5 to 15 bases.

8. The starting fragment compound is 【Chemistry 11】 where Y is 【Chemistry 12】 The starting fragment compound according to claim 7, characterized in that it is

9. a step a) of incubating the compound library with the protein target and then engineering to effect covalent cross-linking; a step b of separating the protein-DNA encoded compound covalently cross-linked complex from uncross-linked DNA encoded compound; Step c. performs PCR amplification and DNA sequencing on the recovered protein-DNA-encoded compound covalently cross-linked complex to read the DNA sequence information and obtain compound structure information; 6. A method for screening a DNA-encoded chemical library according to claim 4 or 5, comprising:

10. The screening method according to claim 9 , wherein in step a, the covalent crosslinking is carried out by light irradiation, heating, electric current or direct incubation.

11. 10. The method of claim 9, wherein the separation method in step b comprises immobilizing the protein and washing with an elution solution to remove unimmobilized substances.

12. The screening method according to claim 11, wherein the protein is immobilized using magnetic beads.

Citation Information

Patent Citations

  • Methods for Synthesis of Encoded Libraries

    JP2007524662A